Literature DB >> 21787192

Pharmacogenomics of cisplatin-induced ototoxicity.

Debashree Mukherjea1, Leonard P Rybak.   

Abstract

Cisplatin ototoxicity affects different individuals in a widely variable manner. These variations are likely to be explained by genetic differences among those affected. It would be highly advantageous to identify genetic variants that predispose to cisplatin ototoxicity in order to minimize the risk to susceptible subgroups. Although this area of research is very important, only a few studies have rigorously examined the genetic basis for cisplatin-induced susceptibility to hearing loss. This article addresses recent progress in clarifying the incidence of cisplatin ototoxicity and the risk factors and controversies regarding the identification of genetic variants associated with cisplatin-induced hearing loss.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21787192      PMCID: PMC3217465          DOI: 10.2217/pgs.11.48

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  79 in total

1.  Theta, a new class of glutathione transferases purified from rat and man.

Authors:  D J Meyer; B Coles; S E Pemble; K S Gilmore; G M Fraser; B Ketterer
Journal:  Biochem J       Date:  1991-03-01       Impact factor: 3.857

2.  Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism.

Authors:  S Pemble; K R Schroeder; S R Spencer; D J Meyer; E Hallier; H M Bolt; B Ketterer; J B Taylor
Journal:  Biochem J       Date:  1994-05-15       Impact factor: 3.857

3.  A catechol-O-methyltransferase that is essential for auditory function in mice and humans.

Authors:  Xin Du; Martin Schwander; Eva Marie Y Moresco; Pia Viviani; Claudia Haller; Michael S Hildebrand; Kwang Pak; Lisa Tarantino; Amanda Roberts; Heather Richardson; George Koob; Hossein Najmabadi; Allen F Ryan; Richard J H Smith; Ulrich Müller; Bruce Beutler
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-15       Impact factor: 11.205

Review 4.  Comparative adverse effect profiles of platinum drugs.

Authors:  M J McKeage
Journal:  Drug Saf       Date:  1995-10       Impact factor: 5.606

5.  Mapping of class alpha glutathione S-transferase 2 (GST-2) genes to the vicinity of the d locus on mouse chromosome 9.

Authors:  M Kasahara; E Matsumura; G Webb; P G Board; F Figueroa; J Klein
Journal:  Genomics       Date:  1990-09       Impact factor: 5.736

Review 6.  Cisplatin ototoxicity and protection: clinical and experimental studies.

Authors:  Leonard P Rybak; Debashree Mukherjea; Sarvesh Jajoo; Vickram Ramkumar
Journal:  Tohoku J Exp Med       Date:  2009-11       Impact factor: 1.848

7.  GSEA-P: a desktop application for Gene Set Enrichment Analysis.

Authors:  Aravind Subramanian; Heidi Kuehn; Joshua Gould; Pablo Tamayo; Jill P Mesirov
Journal:  Bioinformatics       Date:  2007-07-20       Impact factor: 6.937

8.  S-Adenosyl-L-methionine increases serum BUN and creatinine in cisplatin-treated mice.

Authors:  Bernardo Ochoa; Norma Bobadilla; Gerardo Arrellín; Luis A Herrera
Journal:  Arch Med Res       Date:  2009-01       Impact factor: 2.235

9.  Ototoxicity of high-dose cisplatin by bolus administration in patients with advanced cancers and normal hearing.

Authors:  J Kopelman; A S Budnick; R B Sessions; M B Kramer; G Y Wong
Journal:  Laryngoscope       Date:  1988-08       Impact factor: 3.325

10.  Levels of glutathione S transferase pi mRNA in human lung cancer cell lines correlate with the resistance to cisplatin and carboplatin.

Authors:  K Nakagawa; J Yokota; M Wada; Y Sasaki; Y Fujiwara; M Sakai; M Muramatsu; T Terasaki; Y Tsunokawa; M Terada
Journal:  Jpn J Cancer Res       Date:  1988-03
View more
  25 in total

1.  Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss.

Authors:  Heng Xu; Giles W Robinson; Jie Huang; Joshua Yew-Suang Lim; Hui Zhang; Johnnie K Bass; Alberto Broniscer; Murali Chintagumpala; Ute Bartels; Sri Gururangan; Tim Hassall; Michael Fisher; Richard Cohn; Tetsuji Yamashita; Tal Teitz; Jian Zuo; Arzu Onar-Thomas; Amar Gajjar; Clinton F Stewart; Jun J Yang
Journal:  Nat Genet       Date:  2015-02-09       Impact factor: 38.330

2.  Cisplatin-induced ototoxicity and the role of pharmacogenetic testing.

Authors:  Lauren E Wyatt; Mary Jayne Kennedy
Journal:  J Pediatr Pharmacol Ther       Date:  2012-10

3.  Lower carrier rate of GJB2 W24X ancestral Indian mutation in Roma samples from Hungary: implication for public health intervention.

Authors:  Csilla Sipeky; Petra Matyas; Marton Melegh; Ingrid Janicsek; Renata Szalai; Istvan Szabo; Reka Varnai; Greta Tarlos; Alma Ganczer; Bela Melegh
Journal:  Mol Biol Rep       Date:  2014-06-27       Impact factor: 2.316

Review 4.  A Review of Cisplatin-Associated Ototoxicity.

Authors:  Jessica Paken; Cyril D Govender; Mershen Pillay; Vikash Sewram
Journal:  Semin Hear       Date:  2019-04-26

5.  Proposed comprehensive ototoxicity monitoring program for VA healthcare (COMP-VA).

Authors:  Dawn Konrad-Martin; Kelly M Reavis; Garnett McMillan; Wendy J Helt; Marilyn Dille
Journal:  J Rehabil Res Dev       Date:  2014

Review 6.  Cisplatin and aminoglycoside antibiotics: hearing loss and its prevention.

Authors:  Jochen Schacht; Andra E Talaska; Leonard P Rybak
Journal:  Anat Rec (Hoboken)       Date:  2012-10-08       Impact factor: 2.064

Review 7.  Applying U.S. national guidelines for ototoxicity monitoring in adult patients: perspectives on patient populations, service gaps, barriers and solutions.

Authors:  Dawn Konrad-Martin; Gayla L Poling; Angela C Garinis; Candice E Ortiz; Jennifer Hopper; Keri O'Connell Bennett; Marilyn F Dille
Journal:  Int J Audiol       Date:  2017-11-20       Impact factor: 2.117

8.  Prevention of cisplatin-induced ototoxicity by the inhibition of gap junctional intercellular communication in auditory cells.

Authors:  Yeon Ju Kim; Jangho Kim; Chunjie Tian; Hye Jin Lim; Young Sun Kim; Jong Hoon Chung; Yun-Hoon Choung
Journal:  Cell Mol Life Sci       Date:  2014-03-13       Impact factor: 9.261

9.  The curcuminoid, EF-24, reduces cisplatin-mediated reactive oxygen species in zebrafish inner ear auditory and vestibular tissues.

Authors:  Jerry D Monroe; Matthew H Millay; Blaine G Patty; Michael E Smith
Journal:  J Clin Neurosci       Date:  2018-09-20       Impact factor: 1.961

Review 10.  Genetic and Modifiable Risk Factors Contributing to Cisplatin-induced Toxicities.

Authors:  Matthew R Trendowski; Omar El Charif; Paul C Dinh; Lois B Travis; M Eileen Dolan
Journal:  Clin Cancer Res       Date:  2018-10-10       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.